Trial Profile
A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE [bortezomib], and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms LYM-3002 Study
- Sponsors Janssen-Cilag; Takeda Oncology
- 13 Dec 2022 Results(n=525, from two studies SHINE and LYM-3002) assessing comparative analysis of PFS and OS with the I+BR arm from the SHINE study and the R-CHOP and VR-CAP arms from the LYM-3002 trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 18 Oct 2018 Results assessing the overall survival and safety outcomes for patients in the long-term follow-up phase after the primary progression-free-survival endpoint was met, published in the Lancet Oncology.
- 14 Jun 2018 Status changed from active, no longer recruiting to completed.